59-05-032 Proceeding

205 Proceedings of the Princess Maha Chakri Sirindhorn Congress B. Univariate analysis of seizure predictors Table 2 showed demographic data for 691 SLE patients with or without seizure. Comparing seizure group to non-seizure group, photosensitivity, SLE duration (23.6% vs. 11.8%; p = 0.006), serositis (47.2% vs. 34.8%; p = 0.038), proteinuria (75.0% vs. 57.8%; p = 0.006), leukopenia (68.1% vs. 51.0%; p = 0.006), lymphopenia (87.5% vs. 72.8%; p = 0.007), thrombocytopenia (61.1% vs. 42.2%; p = 0.002), psychosis (18.1% vs. 6.1%; p < 0.001), end stage renal disease (23.6% vs. 7.3%; p < 0.001), cerebrovascular disease (20.8% vs. 6.5%; p < 0.001) and mortality rate (37.5% vs. 11.7%; p < 0.001) showed significant difference. However, gender, age at onset, disease duration, other clinical features, and laboratory data such as autoantibody did not differ in seizure group compared with non-seizure group. Table 2 Comparison between SLE patients with and without seizure Yes (n=72) No (n=618) P-value Male (%) 4 (5.6) 74 (12.0) 0.104 Age at onset (yrrs) 36.0 ± 18.3 36.3 ± 16.2 0.889 Age at admission (yrs) 41.2 ± 18.0 40.8 ± 15.8 0.834 SLE duration (yrs) 8.93 ± 7.82 8.53 ± 7.0 0.652 Clinical features Malar rash (%) 34 (47.2) 270 (43.7) 0.627 Discoid rash (%) 9 (12.5) 54 (8.7) 0.308 Photosensitivity (%) 17 (23.6) 73 (11.8) 0.006* Oral ulcer (%) 17 (23.6) 154 (25.0) 0.770 Arthritis (%) 36 (50.0) 323 (52.3) 0.567 Serositis (%) 34 (47.2) 215 (34.8) 0.038* Proteinuria (%) 54 (75.0) 357 (57.8) 0.006* Cellular cast (%) 11 (15.3) 92 (14.9) 0.952 Anemia (%) 28 (38.9) 178 (28.8) 0.080 Leukopenia (%) 49 (68.1) 315 (51.0) 0.006* Lymphopenia (%) 63 (87.5) 450 (72.8) 0.007* Thrombocytopenia (%) 44 (61.1) 261 (42.2) 0.002* Psychosis (%) 13 (18.1) 38 (6.1) < 0.001* C3 level 61.6 ± 31.1 69.3 ± 33.0 0.060 C4 level 12.8 ± 9.42 13.7 ± 9.6 0.410 Anti-dsDNA (+) (%) 48 (66.7) 439 (71.0) 0.417 Anti-dsDNA level 450.9 ± 563.5 42.5 ± 603.0 0.911 Anti-Sm (%) 24 (33.3) 187 (30.3) 0.703 Anti-SSA (%) 35 (48.6) 279 (45.1) 0.738 Anti-SSB (%) 17 (23.6) 132 (21.4) 0.705 Anti-RNP (%) 28 (38.9) 217 (35.1) 0.749